Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies.
As for other drugs, there is a large interindividual variability of the plasma concentrations of antidepressants for a given dose. Within the last 2 decades, a very large number of pharmacogenetic studies have made it possible to understand the importance of genetic factors on the disposition of drugs in the organism, many of them at the levels of drug metabolism. Polymorphism of CYP2D6 and of other drug-metabolizing enzymes may thus lead to very large differences in drug exposure between patients and possibly also to toxicity or ineffective drug concentrations in some subjects. In consequence, dose recommendations of antidepressants based on genotypes, justified by the principle of administering bioequivalent individualized drug doses, are now proposed. However, blood (and thus possibly brain) concentrations also depend on other factors than the genetic makeup of the patients. Therapeutic drug monitoring of antidepressants allows us to take into account the influence of factors such as comedications, diet, smoking habit, impaired organ function, and compliance. Therapeutic drug monitoring and genotyping are thus complementary, and their combined use contributes to improve pharmacotherapy with antidepressants and other drugs.
Eap
C B
CB
Unité de Biochimie et Psychopharmacologie Clinique, Centre de Neurosciences Psychiatriques, Département Universitaire de Psychiatrie Adulte, Hôpital de Cery, CH-1008 Prilly-Lausanne, Switzerland. Chin.Eap@inst.hospvd.ch
Jaquenoud Sirot
E
E
Baumann
P
P
D000928:Antidepressive Agents / Q000378:metabolism*; D002986:Clinical Trials as Topic; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism; D016903:Drug Monitoring / Q000379:methods*; D005838:Genotype; D006801:Humans; D010349:Patient Compliance; D010597:Pharmacogenetics / Q000379:methods*
D000928:Antidepressive Agents; D003577:Cytochrome P-450 Enzyme System